

## Effect of *Lactobacillus gasseri* SBT2055 in fermented milk on abdominal adiposity in adults in a randomised controlled trial

Yukio Kadooka<sup>1\*</sup>, Masao Sato<sup>2</sup>, Akihiro Ogawa<sup>1</sup>, Masaya Miyoshi<sup>1</sup>, Hiroshi Uenishi<sup>1</sup>, Hitomi Ogawa<sup>1</sup>, Ken Ikuyama<sup>3</sup>, Masatoyo Kagoshima<sup>4</sup> and Takashi Tsuchida<sup>5</sup>

<sup>1</sup>Milk Science Research Institute, Megmilk Snow Brand Company Limited, 1-1-2 Minamidai, Kawagoe, Saitama 350-1165, Japan

<sup>2</sup>Laboratory of Nutrition Chemistry, Faculty of Agriculture, Graduate School, Kyushu University, Fukuoka, Japan

<sup>3</sup>Products Development Department, Megmilk Snow Brand Company Limited, Saitama, Japan

<sup>4</sup>Department of Pharmacy, Faculty of Pharmacy, Iwaki Meisei University, Fukushima, Japan

<sup>5</sup>Yokohama Tsuchida Medical Clinic, Yokohama, Kanagawa, Japan

(Submitted 20 November 2012 – Final revision received 5 March 2013 – Accepted 5 March 2013 – First published online 25 April 2013)

### Abstract

Consumption of fermented milk (FM) containing a probiotic, *Lactobacillus gasseri* SBT2055 (LG2055), previously showed a reduction in abdominal adiposity in a randomised controlled trial (RCT) using FM with  $10^8$  colony-forming units (cfu) of LG2055/g. However, whether the effectiveness is observed at lower concentrations, the recommended minimum or intermediate levels of probiotics ( $10^6$  or  $10^7$  cfu/g, respectively), remains to be examined. A multi-centre, double-blind, parallel-group RCT was conducted using 210 healthy Japanese adults with large visceral fat areas ( $80.2\text{--}187.8\text{ cm}^2$ ). They were balanced for their baseline characteristics and randomly assigned to three groups receiving FM containing  $10^7$ ,  $10^6$  or 0 (control) cfu LG2055/g of FM, and were asked to consume 200 g FM/d for 12 weeks. Abdominal visceral fat areas, which were determined by computed tomography, at week 12, changed from baseline by an average of  $-8.5\%$  (95% CI  $-11.9$ ,  $-5.1$ ;  $P<0.01$ ) in the  $10^7$  dose group, and by  $-8.2\%$  (95% CI  $-10.8$ ,  $-5.7$ ;  $P<0.01$ ) in the  $10^6$  dose group. Other measures including BMI, waist and hip circumferences, and body fat mass were also significantly decreased from baseline at week 12 in both groups; interestingly, the cessation of taking FM for 4 weeks attenuated these effects. In the control group, none of these parameters significantly decreased from baseline. These findings demonstrate that consumption of LG2055 at doses as low as the order of  $10^8$  cfu/d exhibited a significant lowering effect on abdominal adiposity, and suggest that constant consumption might be needed to maintain the effect.

**Key words:** Probiotics; Abdominal fat; Computed tomography; Body composition

*Lactobacillus gasseri* strain SBT2055 (LG2055) is a probiotic lactic acid bacterium that originates from the human intestine<sup>(1,2)</sup>. LG2055 has the ability to improve the intestinal environment<sup>(3)</sup> and perform beneficial actions, including the inhibition of dextran sulphate sodium-induced ulcerative colitis in rats<sup>(4)</sup> and the prevention of rotavirus-induced diarrhoea in mice<sup>(5)</sup>. LG2055 has also demonstrated an ability to regulate abdominal adiposity, including the prevention of adipocyte enlargement in rats<sup>(6,7)</sup> and the reduction in the visceral fat area in overweight human subjects in a randomised controlled trial (RCT)<sup>(8)</sup>.

In the previous RCT<sup>(8)</sup>, fermented milk (FM) containing LG2055 at a concentration of  $10^8$  colony-forming units (cfu)/g

was consumed by subjects at a dose of 200 g FM/d for 12 weeks and resulted in significantly reduced visceral fat areas. However, its effectiveness at different doses should be further examined to confirm the appropriateness of the dose that we first tested, and to understand the effective dose range of LG2055. Information on the effective dose range would also be valuable when considering mechanisms of action.

Probiotics are defined as live micro-organisms that when administered in adequate amounts confer a health benefit on the host<sup>(9)</sup>, which also suggests that the administration dose of a probiotic is an important factor in demonstrating probiotic effectiveness. Probiotic-containing dairy products are generally recommended to contain approximately

**Abbreviations:** cfu, colony-forming units; FM, fermented milk; IEC, intestinal epithelial cells; LG2055, *Lactobacillus gasseri* strain SBT2055; RCT, randomised controlled trial.

\* **Corresponding author:** Y. Kadooka, email y-kadooka@meg-snow.com

$10^6$  cfu/g or more of probiotics<sup>(10,11)</sup>. This concentration, however, is not based on specific mechanisms of action or studies in clinical settings; rather, it has been set up to compensate for a possible decline in viable counts of probiotics during storage. It has also been suggested that dose–response studies with probiotics should be performed in a probiotic strain-dependent manner for a specific health target<sup>(12)</sup>. Thus, when taking account of the use of LG2055 in actual dairy products, it is important to examine whether LG2055 demonstrates anti-adiposity effects at concentrations as low as  $10^6$  cfu/g, the recommended minimum level for probiotic bacteria in FM products. Additionally, there are no reported studies examining the administration dose of probiotics and its effect on abdominal adiposity.

In the present study, a multi-centre, double-blind, parallel-group RCT was conducted to examine whether consumption of FM containing LG2055 at concentrations of  $10^6$  and  $10^7$  cfu/g, which are the recommended minimum or intermediate level of probiotics, respectively, exhibits lowering effects on abdominal adiposity, anthropometric measures and body composition in adults with large visceral fat areas.

## Subjects and methods

### Subjects

A total of 210 healthy Japanese adults (105 men and 105 women, aged 35–60 years) with large visceral fat areas ( $80.2$ – $187.8$  cm<sup>2</sup>) were enrolled for the study. The cut-off value of the visceral fat area for the enrolment was set to  $80.0$  cm<sup>2</sup> in accordance with a study conducted in Japan<sup>(13)</sup>, in which the value has been suggested as appropriate when pre-menopausal women are included in the study group. Those with serious disorders, including internal organ diseases, diabetes and hypersensitivity to dairy products, were excluded. No subjects dropped out due to adverse events after the initiation of the study.

### Study design

The present study was performed as a multi-centre, double-blind, parallel-group RCT. The protocol was in accordance with the Declaration of Helsinki, and was approved by the Institutional Review Board of Yokohama Tsuchida Medical Clinic (Yokohama, Kanagawa, Japan) before the initiation of the study. Subjects provided written informed consent before the study began. The study was conducted by a contract research organisation, ESUCAL Laboratories Company, Limited (Omiya, Saitama, Japan) and was performed from July 2011 to January 2012 at the following nine facilities in Japan: Yokohama Tsuchida Medical Clinic (Yokohama, Kanagawa); Ageo Kousei Hospital (Ageo, Saitama); Yuki Clinic (Shibuya-ku, Tokyo); Ishiguro Clinic (Gifu, Gifu); Kameido-minamiguchi Clinic (Koto-ku, Tokyo); Mizuno Internal Medical Clinic (Tokorozawa, Saitama); Sakuragaoka Central Hospital (Yamato, Kanagawa); Fuefuki Central Hospital (Fuefuki, Yamanashi); Higashi Kawaguchi Hospital (Kawaguchi, Saitama).

### Primary outcome

The change in abdominal visceral fat area from baseline was applied as the primary outcome.

### Sample size calculation

Sample size calculation was based on the result of the previous study's primary outcome of abdominal visceral fat area in the active group<sup>(8)</sup>, in which the average amount of change from baseline to week 12 was  $5.82$  with a SD of  $13.48$ : these parameters yielded a power of  $0.79$  with  $n$  43 per group for the paired  $t$  test at a  $0.05$  significance level.

To estimate the sample size for the present study, those parameters were applied again in the calculation of the paired  $t$  test at a significance level of  $0.017$  (Bonferroni correction for three comparisons) to fulfil a power of  $0.85$ . This calculation produced a minimum required number of sixty-seven per group. Therefore, a total of 210 subjects at sixty-nine to seventy-one subjects per group in the present study were sufficient to give a power of  $0.85$ .

### Probiotic fermented milk

FM was prepared with lactic acid bacteria starter cultures (*Streptococcus thermophilus* and *Lactobacillus delbrueckii* ssp. *bulgaricus*) commonly used in conventional yogurt production. LG2055 cells at levels of  $10^7$ ,  $10^6$  and  $0$  (control) cfu/g were then added. In detail, a non-FM base for the production of FM consisted of approximately 11% skimmed milk powder and a small amount of flavouring, agar and sucralose as a zero-energy artificial sweetener. This base was inoculated with the starter cultures and LG2055 cells, and then cultured at  $40^\circ\text{C}$  for 3.5 to 4 h. The viable cell counts of LG2055, monitored in every production using a selection medium<sup>(7)</sup>, were  $7.9$  (SD  $1.1$ )  $\times 10^7$ ,  $6.9$  (SD  $3.5$ )  $\times 10^6$  and  $0$  cfu/g for each dose group, respectively. The viable cell counts of the starter cultures for yogurt, which used a standard brom-cresol purple medium, was  $1.2$  (SD  $0.2$ )  $\times 10^9$  cfu/g. FM were identical in energy ( $146$  kJ (35 kcal)), protein ( $3.7$  g), fat ( $0.1$  g), carbohydrate ( $4.9$  g), Na ( $41$  mg) and Ca ( $120$  mg) content per 100 g; they were also indistinguishable in taste. FM were kept in cold storage and delivered weekly.

### Study schedule and protocol

The study period consisted of a 4-week lead-in period in which initial parameters were obtained for baseline measurements, followed by a 12-week consumption period where initiation of consumption was designated as week 0, and a 4-week post-consumption period.

To minimise the imbalance between the groups, subjects were carefully matched for sex, age, initial BMI and visceral fat area within the medical facilities, and then randomly assigned by an independent researcher (M. K.) to three groups receiving FM containing LG2055 at levels of  $10^7$ ,  $10^6$  or  $0$  (control) cfu/g. Subjects consumed 200 g, as two portions

of 100 g, of FM every day for 12 weeks, while they maintained their habitual mode of living including diet and exercise.

After the initiation of consumption, anthropometric measures and body composition were measured at weeks 4, 8 and 12 weeks and at 4 weeks after the completion of consumption. Abdominal computed tomography scans for the measurement of abdominal fat areas were carried out at weeks 8 and 12.

Each subject made a daily record of FM consumption, diet and exercise, including the number of steps walked and physical condition. Compliance was high: the frequencies of FM consumption were 99.2 (SD 1.4), 98.9 (SD 1.6) and 99.0 (SD 1.6)% in the 10<sup>7</sup>, 10<sup>6</sup> and control groups, respectively. Subjects also made a detailed dietary record for three consecutive days before each measurement: at the start of consumption (week 0), weeks 4, 8, 12 and at 4 weeks after the completion of consumption. The dietary record was analysed by an administrative dietitian to determine the intake of energy, protein, carbohydrate, fat and Ca using Healthy Maker Pro 501 software (Mushroom Soft Company Limited).

Subjective symptoms were checked at each measurement, including headache, nausea and abdominal pain, and blood testing was conducted during an interview with a doctor.

#### Abdominal fat area

Four-slice abdominal computed tomography scans were taken at the level of lumbar 4–5 vertebra, with a 120 kVp tube voltage, 240 mAs tube current, 10 mm slice thickness and

450 mm field of view. Computed tomography scan images were analysed using Fat Scan version 4 software (East Japan Institute of Technology Company Limited) to obtain abdominal visceral and subcutaneous fat areas.

#### Anthropometric measures and body composition

Height was measured using a stadiometer. Waist circumference was measured at the level of the umbilicus, and hip circumference was measured at the level of the maximal extension of the buttocks. Body weight and body fat percentage (the bioelectrical impedance method) were measured using a scale for body composition (Inner Scan 50; Tanita). BMI was calculated as body weight (kg)/height (m<sup>2</sup>). Body fat mass and lean body mass were calculated using body fat percentage and body weight.

#### Statistical analysis

The SPSS statistical software package 15.0J for Windows (SPSS Japan, Inc.) was used for statistical analyses. Normality and equality of variances were confirmed using the Shapiro–Wilk test and Levene's test, respectively. The interaction between the experimental group and the consumption period of time (group × time interaction) was analysed using repeated-measures ANOVA. Within-group comparisons between baseline and each subsequent time point were carried out using repeated-measures ANOVA followed by Bonferroni multiple comparisons. The between-group comparisons were

**Table 1.** Baseline characteristics of the subjects (Mean values and standard deviations)

Parameters*	10 <sup>7</sup> dose		10 <sup>6</sup> dose		Control	
	Mean	SD	Mean	SD	Mean	SD
Sex <i>n</i>	69		71		70	
Male	33		36		36	
Female	36		35		34	
Age (years)	46.9	7.4	47.2	7.4	47.4	7.0
Anthropometric measures						
Height (cm)	164.3	9.0	164.7	9.3	166.2	9.2
Body weight (kg)	74.5	10.2	74.0	9.7	75.5	11.2
BMI (kg/m <sup>2</sup> )	27.5	1.9	27.2	1.8	27.2	1.9
Waist (cm)	93.9	5.9	93.0	6.1	94.6	6.9
Hip (cm)	100.1	5.0	99.9	5.2	100.7	5.8
Abdominal fat areas						
Visceral (cm <sup>2</sup> )	114.3	23.4	115.6	23.0	116.3	25.8
Subcutaneous (cm <sup>2</sup> )	262.2	74.1	254.8	75.4	253.2	77.2
Body composition						
Fat percentage (%)	32.6	7.3	32.1	7.3	32.2	7.3
Fat mass (kg)	24.0	4.9	23.5	5.6	24.2	6.4
Lean mass (kg)	50.5	10.5	50.5	9.5	51.3	10.2
Nutrient intake						
Energy						
kJ/d	7518.9	1076.6	7350.6	1103.4	7523.1	1197.6
kcal/d	1796.2	257.2	1756.0	263.6	1797.2	286.1
Protein (g/d)	64.0	12.1	62.2	11.1	63.7	12.5
Carbohydrate (g/d)	247.3	41.1	240.0	43.4	248.1	42.9
Fat (g/d)	54.5	13.8	54.1	12.1	54.7	13.2
Ca (mg/d)	340.3	119.6	344.0	127.5	345.1	143.8
Steps walked (counts/d)	7861	2953	7965	2460	8502	3283

\* No parameters were statistically significantly different between the experimental groups by one-way ANOVA.

performed using the amount of change from baseline to each subsequent time point by applying a one-way ANOVA followed by Bonferroni multiple comparisons. A *P* value of less than 0.05 was considered as statistically significant.

## Results

### Baseline characteristics of the subjects

Table 1 shows no statistically significant differences in any parameters of the baseline characteristics among the three groups. Nutrient intake, including Ca, which is well known for its regulatory effects on obesity, and the number of steps walked were also not significantly altered from each baseline during the study period (data not shown).

### Abdominal fat areas

Table 2 shows that the group × time interaction was statistically significant for the abdominal visceral fat area, indicating that the pattern of changes from baseline over time differed and depended on the dose of LG2055. No significant differences were observed in abdominal subcutaneous fat areas. Visceral fat areas in both the 10<sup>7</sup> and 10<sup>6</sup> dose groups decreased significantly at weeks 8 and 12 from baseline (within-group comparisons); however, a reduction was not observed in the control group. The amount of changes at week 12 was significant in both the 10<sup>7</sup> and 10<sup>6</sup> dose groups against the control group (between-group comparisons).

### BMI, waist and hip circumferences

Table 3 shows that group × time interactions were significant for BMI, waist and hip circumferences. All these measures

were significantly reduced in both the 10<sup>7</sup> and 10<sup>6</sup> dose groups at weeks 8 and 12 from baseline (within-group comparisons); a reduction was not observed in the control group. The amount of changes was significant in all the measures at week 12 in both the 10<sup>7</sup> and 10<sup>6</sup> dose groups against the control group (between-group comparisons). At 4 weeks after the completion of consumption, the amount of changes in all the measures in both the 10<sup>7</sup> and 10<sup>6</sup> dose groups became smaller than that observed at week 12; the waist and hip measurements in the 10<sup>7</sup> and 10<sup>6</sup> dose groups were not significantly different from the control group; however, these measurements were significantly different from baseline.

### Body composition

Table 4 shows that group × time interactions were significant for fat percentage, fat mass and lean mass; however, only fat mass demonstrated a significant decrease at week 12 both from baseline (within-group comparisons) and against the control (between-group comparisons) in both the 10<sup>7</sup> and 10<sup>6</sup> dose groups. At 4 weeks after the completion of consumption, the amount of changes in fat mass that were observed at week 12 in both the 10<sup>7</sup> and 10<sup>6</sup> dose groups was reduced and their significance from baseline had disappeared.

### Daily life and adverse events

No irregularities in daily life or adverse events related to the consumption of FM were observed throughout the study according to the daily record and an interview with a doctor. Blood test results (TAG, total, LDL- and HDL-cholesterol, NEFA, acetoacetic acid, 3-hydroxybutyric acid, total ketone body, lipoprotein, blood glucose, HbA1c, insulin, aspartate

**Table 2.** Percentage changes and corresponding measures from baseline in abdominal fat areas (Mean values and 95% confidence intervals)

Parameters	Group	Week 8		Week 12		
		Mean	95% CI	Mean	95% CI	
Visceral ‡	10 <sup>7</sup> dose					
	%	-4.8**	-7.6, -1.9	-8.5**†	-11.9, -5.1	
	cm <sup>2</sup>	-5.3	-8.4, -2.2	-9.6	-14.3, -4.9	
	10 <sup>6</sup> dose					
	%	-5.6**	-8.1, -3.1	-8.2**†	-10.8, -5.7	
	cm <sup>2</sup>	-5.8	-8.3, -3.2	-8.6	-11.3, -5.9	
Control	%	-1.2	-4.1, 1.7	-0.7	-3.8, 2.5	
	cm <sup>2</sup>	-1.3	-4.5, 2.0	-0.4	-4.1, 3.2	
	Subcutaneous	10 <sup>7</sup> dose				
		%	-1.6	-3.3, 0.0	-2.6*	-4.6, -0.6
		cm <sup>2</sup>	-4.5	-11.2, 2.2	-6.8	-14.3, 0.7
		10 <sup>6</sup> dose				
%		-0.5	-1.7, 0.8	-1.2	-2.5, 0.1	
cm <sup>2</sup>		-1.3	-3.9, 1.3	-2.8	-5.2, -0.3	
Control	%	0.0	-1.2, 1.2	-0.4	-1.8, 1.1	
	cm <sup>2</sup>	0.8	-2.0, 3.7	0.0	-3.2, 3.3	

Mean values were significantly different for within-group comparisons from baseline: \* *P* < 0.05, \*\* *P* < 0.01.

† Mean values were significantly different for between-group comparisons from control (*P* < 0.05).

‡ There was a significant group × time interaction effect (*P* < 0.05).

**Table 3.** Percentage changes and corresponding measures from baseline in BMI, waist and hip (Mean values and 95 % confidence intervals)

Parameters	Groups	Week 8		Week 12		4 weeks after finishing consumption	
		Mean	95 % CI	Mean	95 % CI	Mean	95 % CI
BMI ††	10 <sup>7</sup> dose						
	%	-0.6**†	-1.0, -0.2	-1.1**††	-1.6, -0.6	-0.5	-0.9, 0.0
	kg/m <sup>2</sup>	-0.2	-0.3, -0.1	-0.3	-0.4, -0.2	-0.1	-0.3, 0.0
	10 <sup>6</sup> dose						
	%	-1.0**††	-1.4, -0.6	-1.6**††	-2.1, -1.1	-0.6*†	-1.0, -0.1
	kg/m <sup>2</sup>	-0.3	-0.4, -0.2	-0.4	-0.5, -0.3	-0.2	-0.3, 0.0
Waist ††	Control						
	%	0.3	0.0, 0.6	0.3	-0.1, 0.7	0.4	0.0, 0.8
	kg/m <sup>2</sup>	0.1	0.0, 0.2	0.1	-0.1, 0.2	0.1	0.0, 0.3
	10 <sup>7</sup> dose						
	%	-0.9**†	-1.3, -0.6	-1.4**††	-1.8, -1.0	-0.8**	-1.3, -0.4
	cm	-0.9	-1.2, -0.5	-1.3	-1.7, -0.9	-0.8	-1.2, -0.4
Hip ††	10 <sup>6</sup> dose						
	%	-0.8**	-1.2, -0.4	-1.2**††	-1.7, -0.7	-0.7**	-1.2, -0.2
	cm	-0.7	-1.1, -0.4	-1.1	-1.5, -0.7	-0.7	-1.1, -0.3
	Control						
	%	0.0	-0.4, 0.3	-0.1	-0.4, 0.3	-0.2	-0.6, 0.2
	cm	-0.1	-0.4, 0.3	-0.1	-0.5, 0.3	-0.2	-0.7, 0.3
Hip ††	10 <sup>7</sup> dose						
	%	-0.8**†	-1.0, -0.5	-1.2**††	-1.5, -0.9	-0.5**	-0.8, -0.2
	cm	-0.8	-1.0, -0.5	-1.2	-1.5, -0.9	-0.5	-0.8, -0.2
	10 <sup>6</sup> dose						
	%	-0.5**	-0.8, -0.3	-0.9**††	-1.1, -0.6	-0.3*	-0.6, -0.1
	cm	-0.6	-0.8, -0.3	-0.9	-1.1, -0.6	-0.4	-0.6, -0.1
Control	%	-0.2	-0.4, 0.0	-0.2	-0.4, 0.1	-0.2	-0.4, 0.1
	cm	-0.2	-0.5, 0.1	-0.2	-0.5, 0.1	-0.2	-0.5, 0.2

Mean values were significantly different for within-group comparisons from baseline: \* $P < 0.05$ , \*\* $P < 0.01$ . Mean values were significantly different for between-group comparisons from control: † $P < 0.05$ , †† $P < 0.01$ . †† There was a significant group  $\times$  time interaction effect ( $P < 0.01$ ).

aminotransferase, alanine aminotransferase,  $\gamma$ -glutamyltranspeptidase, alkaline phosphatase, L-lactate dehydrogenase, total protein, albumin, uric acid, blood urea N, creatinine, Na, Cl, K, Ca, P, Mg, Fe, leucocytes, erythrocytes, Hb, haematocrit and platelets) also showed that all measurements were within normal ranges and no physiologically significant changes were observed throughout the study (data not shown).

## Discussion

The present study demonstrated a significant reduction in abdominal visceral fat area after the consumption of FM containing probiotic LG2055, at concentrations of 10<sup>6</sup> and 10<sup>7</sup> cfu/g. LG2055 at these levels showed the same potency at 10<sup>8</sup> cfu/g which was used in our previous RCT: the average percentage change from baseline was -4.6% (95% CI -7.9, -1.3)<sup>(8)</sup>. The present study, however, did not present a significant reduction in abdominal subcutaneous fat area which was observed in our previous RCT, suggesting a possible diminution of effectiveness at lower doses than the previous study's. Similar to our previous RCT, other measures, including BMI, waist and hip circumferences, and body fat mass, were significantly reduced from baseline at the two doses tested. Interestingly, when looking at anthropometric (Table 3) and body composition measurements (Table 4, except for lean mass), the amount of changes observed in the treatment

groups at week 12 (the end of the consumption period) decreased in magnitude by the time of the 4-week follow-up visit (week 16), and became close to baseline measurements. Fat mass appeared to be the most affected in view of the extent of the amount of change and the disappearance of significance from baseline. This also suggested that continuous consumption of LG2055 was necessary to maintain its effectiveness.

The study conditions of the present and previous RCT were essentially identical to each other except for the doses of LG2055; the baseline characteristics of the subjects were also approximately the same between the studies in that they were healthy but having large visceral fat areas. Energy intake and physical activity estimated from daily and dietary records were considered normal, as shown in Table 1, which was also observed in the previous RCT. However, the existence of under-reporting<sup>(14,15)</sup>, which is pointed out as unavoidable in a number of studies, can also not be denied in the present study, suggesting a possibility that unreported extra energy intake over time caused the obese tendency in the subjects examined. For this reason, the energy intake data in Table 1 should primarily be interpreted as there being no significant differences between the groups during the study period. Nevertheless, it is also undeniable that factors other than energy balance, for example aspects of a modern lifestyle, such as staying up late at night and various

**Table 4.** Percentage changes and corresponding measures from baseline in body composition (Mean values and 95 % confidence intervals)

Parameters	Groups	Week 8		Week 12		4 weeks after finishing consumption	
		Mean	95 % CI	Mean	95 % CI	Mean	95 % CI
Fat percentage ††	10 <sup>7</sup> dose						
	%	-0.4	-1.3, 0.6	-1.4**††	-2.4, -0.3	0.2††	-0.8, 1.2
	Value (%)	-0.2	-0.5, 0.1	-0.5	-0.8, -0.1	0.0	-0.3, 0.3
	10 <sup>6</sup> dose						
	%	0.2	-0.6, 1.0	-0.6††	-1.6, 0.3	0.2††	-0.7, 1.1
	Value (%)	0.1	-0.1, 0.3	-0.2	-0.4, 0.1	0.1	-0.2, 0.4
Fat mass ††	Control						
	%	1.2**	0.6, 1.9	1.9**	1.1, 2.7	2.9**	2.0, 3.8
	Value (%)	0.4	0.1, 0.6	0.6	0.3, 0.9	0.9	0.5, 1.2
	10 <sup>7</sup> dose						
	%	-0.9†	-2.1, 0.4	-2.4**††	-3.8, -0.9	-0.2††	-1.6, 1.2
	kg	-0.3	-0.6, 0.0	-0.6	-1.0, -0.3	-0.1	-0.4, 0.2
Lean mass ††	10 <sup>6</sup> dose						
	%	-0.8†	-1.9, 0.2	-2.2**††	-3.4, -1.0	-0.3††	-1.5, 0.8
	kg	-0.2	-0.4, 0.0	-0.5	-0.7, -0.2	0.0	-0.3, 0.2
	Control						
	%	1.5**	0.7, 2.3	2.2**	1.2, 3.3	3.3**	2.2, 4.5
	kg	0.4	0.1, 0.6	0.5	0.2, 0.8	0.7	0.4, 1.1
Lean mass ††	10 <sup>7</sup> dose						
	%	-0.3	-0.7, 0.0	-0.4*	-0.8, -0.1	-0.5*	-0.8, -0.1
	kg	-0.2	-0.3, 0.0	-0.2	-0.4, 0.0	-0.2	-0.4, 0.0
	10 <sup>6</sup> dose						
	%	-1.1**†	-1.5, -0.8	-1.4**	-1.9, -0.9	-0.7**	-1.2, -0.2
	kg	-0.6	-0.7, -0.4	-0.7	-0.9, -0.5	-0.4	-0.6, -0.2
Lean mass ††	Control						
	%	-0.3	-0.6, 0.1	-0.6**	-0.9, -0.3	-0.9**	-1.3, -0.5
	kg	-0.1	-0.4, 0.1	-0.3	-0.5, -0.1	-0.5	-0.7, -0.2

Mean values were significantly different for within-group comparisons from baseline: \*  $P < 0.05$ , \*\*  $P < 0.01$ .

Mean values were significantly different for between-group comparisons from control: †  $P < 0.05$ , ††  $P < 0.01$ .

†† There was a significant group  $\times$  time interaction effect ( $P < 0.01$ ).

kinds of stress<sup>(16,17)</sup>, and a possible ethnic propensity to accumulate fat in the abdomen<sup>(18)</sup>, might be involved in the obese tendency, although exact causes are not clear.

Of particular significance in the present study is that significant decreases in abdominal visceral adiposity and other body measures were observed at doses as low as the order of 10<sup>8</sup> cfu/d of LG2055 in 200 g FM consumed. Consideration was then given to the effectiveness observed at the lower dose in terms of the relative abundance of LG2055 ingested against indigenous bacterial number in the upper part of the intestine, which is initially accessible to orally fed LG2055. The upper two-thirds of the small intestine (duodenum and jejunum) normally harbour around no more than 10<sup>4</sup> indigenous bacteria/g of its intestinal content<sup>(19–21)</sup>, and this bacterial number is significantly small compared with that in the large intestine (around 10<sup>11</sup> bacteria/g). Although an exact comparison cannot be made, we speculate that the consumption dose of LG2055 (as low as 10<sup>8</sup> cfu/d) could be considered to be relatively abundant in the number of bacterial cells in the upper small intestine. In addition to this relative abundance, frequent and long-term consumption, daily for 12 weeks, may enable LG2055 to interact with the intestine, producing a state of transient 'colonisation'. It has been suggested that even 'transient colonisation' provides substantial physiological effects<sup>(22)</sup>.

A physiological effect that could lead to a reduction in abdominal adiposity would be possible through the interaction between LG2055 and intestinal epithelial cells (IEC). Ingested LG2055 in transient colonisation would mostly interact with IEC, given that IEC constitute the majority of the intestinal wall. IEC have an ability to recognise microbial components of probiotics through their receptors, and recognition is closely linked with the maintenance of intestinal homeostasis, including controlling intestinal inflammation and integrity<sup>(23–26)</sup>. It is also reported that the lack of a recognition system causes disturbance to homeostasis<sup>(27)</sup>. Intestinal disturbance can be provoked by various stimulators, such as bacterial endotoxin of Gram-negative bacteria in the intestine and even a high-fat diet<sup>(28,29)</sup>. Disturbance includes intestinal inflammation and loss of intestinal integrity, which have recently been highlighted as crucial factors causing abdominal adiposity independently of higher energy intake: mice that received an experimental infusion of endotoxin showed obesity despite having a normal diet<sup>(30)</sup>, and mice lacking sensitivity to endotoxin were resistant to obesity, even though they were fed a high-fat diet<sup>(31)</sup>. The probiotic LG2055 has the potential to prevent intestinal inflammation caused by an irritant<sup>(4)</sup>. We suggest that ingested LG2055, recognised by IEC, might help enhance the anti-inflammatory and integrity-maintaining mechanisms of IEC, contributing to a reduction in abdominal adiposity.

It is also worth noting that the test FM containing both LG2055 and yogurt cultures reduced abdominal adiposity when compared with the control FM containing yogurt cultures alone, even though the bacterial counts of LG2055 ( $10^6$  and  $10^7$  cfu/g) were lower than those in the yogurt cultures ( $10^9$  cfu/g). Such superiority of LG2055 over yogurt cultures in exerting anti-obesity effects has also been demonstrated in our previous examination using rats. We reported that the LG2055-fed group had a greater effect in preventing an enlargement in mesenteric adipocyte size compared with the yogurt culture group<sup>(7)</sup>. Further investigation is underway on the mechanisms underlying the advantageous effectiveness of LG2055.

Compositional alteration in the intestinal microbiota would not be a prerequisite for lowering abdominal adiposity. Our preliminary examination in mice (H Uenishi and H Ogawa, unpublished results) showed that mice fed a high-fat diet containing LG2055 at  $10^8$  cfu/g had significant lower abdominal adiposity. However, microbial gene analysis by real-time quantitative PCR of the caecum revealed no significant difference in the levels of predominant phylogenetic groups in the intestine<sup>(32)</sup> (*Clostridium coccoides* group, *Clostridium leptum* group, *Bacteroides fragilis* group, *Atopobium* cluster, *Bifidobacterium* and *Prevotella*). The only significant difference was the detection of ingested LG2055 in the LG2055-fed group compared with the control group.

It is unknown whether the composition of colonic microbiota has a direct influence on abdominal adiposity; the relationship between obesity and alteration in the intestinal microbiota remains inconclusive<sup>(33,34)</sup>. Furthermore, the ease by which microbiota are altered by the diet<sup>(35,36)</sup> and various environmental factors, including genetics and age, makes it difficult to discuss the causal relationship between adiposity and intestinal microbiota. Subjects in the present study maintained their habitual mode of living, including diet, and no strict dietary control was applied. To address the relationship between adiposity and intestinal microbiota, examination under a strict diet, together with the latest methodology, such as advanced sequencing technology coupled with bioinformatics, would be required.

In summary, the present study demonstrated that consumption of LG2055 at doses as low as the order of  $10^8$  cfu/d exhibited a significant lowering effect on abdominal adiposity in adults with large visceral fat areas. Other measures including BMI, waist and hip circumferences, and body fat mass were also significantly decreased from baseline. However, these measures decreased in magnitude by the time of the 4-week follow-up visit after completion of the 12-week consumption period, suggesting that constant ingestion is necessary.

### Acknowledgements

We are grateful to Satoshi Higurashi, Ken Ukibe, Maya Yamashita, Michio Kawano, Tomohiro Hosoya and Humihiko Sakai for their skilful collaboration and useful suggestions. The present study received no specific grant from any funding agency in the public, commercial or not-for-profit sectors. The contributions of the authors were as follows: Y. K. was

the primary author and responsible for the study; M. S. supervised the study design and commented on the paper; A. O., M. M., H. U. and H. O. assisted with the data analysis and interpretation; K. I. was responsible for the test FM's production and quality check; M. K. was responsible for the random assignment of the subjects as an independent researcher; T. T. supervised all the aspects of the study. The authors declare no conflict of interest.

### References

1. Seto Y, Kimura A, Akai Y, *et al.* (2003) Distribution of the *Lactobacillus acidophilus* complex in human fecal specimens examined by restriction fragment length polymorphism of the 16S rRNA genes. *Biosci Microflora* **22**, 75–83.
2. Takahashi H, Fujita T, Suzuki Y, *et al.* (2006) Monitoring and survival of *Lactobacillus gasseri* SBT2055 in the human intestinal tract. *Microbiol Immunol* **50**, 867–870.
3. Fujiwara S, Seto Y, Kimura A, *et al.* (2001) Establishment of orally-administered *Lactobacillus gasseri* SBT2055SR in the gastrointestinal tract of humans and its influence on intestinal microflora and metabolism. *J Appl Microbiol* **90**, 343–352.
4. Imai E, Fukui K, Ohta N, *et al.* (2002) Effects of *Lactobacillus gasseri* SBT2055 on dextran sulfate sodium-induced ulcerative colitis model in rats. *Biosci Microflora* **21**, 179–183.
5. Kadooka Y, Tominari K, Sakai F, *et al.* (2012) Prevention of rotavirus-induced diarrhea by preferential secretion of IgA in breast milk via maternal administration of *Lactobacillus gasseri* SBT2055. *J Pediatr Gastroenterol Nutr* **55**, 66–71.
6. Sato M, Uzu K, Yoshida T, *et al.* (2008) Effects of milk fermented by *Lactobacillus gasseri* SBT2055 on adipocyte size in rats. *Br J Nutr* **99**, 1013–1017.
7. Kadooka Y, Ogawa A, Ikuyama K, *et al.* (2011) The probiotic *Lactobacillus gasseri* SBT2055 inhibits enlargement of visceral adipocytes and upregulation of serum soluble adhesion molecule (sICAM-1) in rats. *Int Dairy J* **21**, 623–627.
8. Kadooka Y, Sato M, Imaizumi K, *et al.* (2010) Regulation of abdominal adiposity by probiotics (*Lactobacillus gasseri* SBT2055) in adults with obese tendencies in a randomized controlled trial. *Eur J Clin Nutr* **64**, 636–643.
9. Food and Agriculture Organization of the United Nations & World Health Organization (2001) *Evaluation of Health and Nutritional Properties of Powder Milk and Live Lactic Acid Bacteria*. FAO/WHO Expert Consultation, Cordoba, Argentina. [ftp://ftp.fao.org/es/esn/food/probio\\_report\\_en.pdf](ftp://ftp.fao.org/es/esn/food/probio_report_en.pdf)
10. Sanders ME (2003) Probiotics: considerations for human health. *Nutr Rev* **61**, 91–99.
11. Vasiljevic T & Shah NP (2008) Probiotics – from Metchnikoff to bioactives. *Int Dairy J* **18**, 714–728.
12. Sanders ME (2008) Probiotics: definition, sources, selection, and uses. *Clin Infect Dis* **46**, S58–S61.
13. Shigematsu R, Okura T, Kumagai S, *et al.* (2006) Cutoff and target values for intra-abdominal fat area for prevention of metabolic disorders in pre- and post-menopausal obese women before and after weight reduction. *Circ J* **70**, 110–114.
14. Garriguet D (2008) Impact of identifying plausible respondents on the under-reporting of energy intake in the Canadian Community Health Survey. *Health Rep* **19**, 47–55.
15. Murakami K, Sasaki S & Okubo H (2012) Characteristics of under- and over-reporters of energy intake among young Japanese women. *J Nutr Sci Vitaminol (Tokyo)* **58**, 253–262.



16. Buijs RM & Kreier F (2006) The metabolic syndrome: a brain disease? *J Neuroendocrinol* **18**, 715–716.
17. Kyrou I, Chrousos GP & Tsigos C (2006) Stress, visceral obesity, and metabolic complications. *Ann N Y Acad Sci* **1083**, 77–110.
18. Sniderman AD, Bhopal R, Prabhakaran D, *et al.* (2007) Why might South Asians be so susceptible to central obesity and its atherogenic consequences? The adipose tissue overflow hypothesis. *Int J Epidemiol* **36**, 220–225.
19. Hao WL & Lee YK (2004) Microflora of the gastrointestinal tract: a review. *Methods Mol Biol* **268**, 491–502.
20. Gorbach SL (1996) Microbiology of the gastrointestinal tract. In *Medical Microbiology*, 4th ed., chapter 95 [S Baron, editor]. Galveston, TX: University of Texas Medical Branch at Galveston.
21. Peach SL & Tabaqchali S (1984) Some studies of the bacterial flora associated with the mucosa of the human gastrointestinal tract. *Nahrung* **28**, 627–634.
22. Hoffmann M, Rath E, Holzwimmer G, *et al.* (2008) *Lactobacillus reuteri* 100-23 transiently activates intestinal epithelial cells of mice that have a complex microbiota during early stages of colonization. *J Nutr* **138**, 1684–1691.
23. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, *et al.* (2004) Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. *Cell* **118**, 229–241.
24. Cario E (2008) Barrier-protective function of intestinal epithelial Toll-like receptor 2. *Mucosal Immunol* **1**, S62–S66.
25. Ey B, Eyking A, Gerken G, *et al.* (2009) TLR2 mediates gap junctional intercellular communication through connexin-43 in intestinal epithelial barrier injury. *J Biol Chem* **284**, 22332–22343.
26. Lee J, Mo JH, Shen C, *et al.* (2007) Toll-like receptor signaling in intestinal epithelial cells contributes to colonic homeostasis. *Curr Opin Gastroenterol* **23**, 27–31.
27. Cario E, Gerken G & Podolsky DK (2007) Toll-like receptor 2 controls mucosal inflammation by regulating epithelial barrier function. *Gastroenterology* **132**, 1359–1374.
28. Ding S, Chi MM, Scull BP, *et al.* (2010) High-fat diet: bacteria interactions promote intestinal inflammation which precedes and correlates with obesity and insulin resistance in mouse. *PLoS One* **5**, e12191.
29. Ding S & Lund PK (2011) Role of intestinal inflammation as an early event in obesity and insulin resistance. *Curr Opin Clin Nutr Metab Care* **14**, 328–333.
30. Cani PD, Amar J, Iglesias MA, *et al.* (2007) Metabolic endotoxemia initiates obesity and insulin resistance. *Diabetes* **56**, 1761–1772.
31. Tsukumo DM, Carvalho-Filho MA, Carvalheira JB, *et al.* (2007) Loss-of-function mutation in Toll-like receptor 4 prevents diet-induced obesity and insulin resistance. *Diabetes* **56**, 1986–1998.
32. Matsuki T, Watanabe K, Fujimoto J, *et al.* (2004) Use of 16S rRNA gene-targeted group-specific primers for real-time PCR analysis of predominant bacteria in human feces. *Appl Environ Microbiol* **70**, 7220–7228.
33. Fleissner CK, Huebel N, Abd El-Bary MM, *et al.* (2010) Absence of intestinal microbiota does not protect mice from diet-induced obesity. *Br J Nutr* **104**, 919–929.
34. Conterno L, Fava F, Viola R, *et al.* (2011) Obesity and the gut microbiota: does up-regulating colonic fermentation protect against obesity and metabolic disease? *Genes Nutr* **6**, 241–260.
35. Hildebrandt MA, Hoffmann C, Sherrill-Mix SA, *et al.* (2009) High-fat diet determines the composition of the murine gut microbiome independently of obesity. *Gastroenterology* **137**, 1716–1724.
36. Queipo-Ortuno MI, Boto-Ordonez M, Murri M, *et al.* (2012) Influence of red wine polyphenols and ethanol on the gut microbiota ecology and biochemical biomarkers. *Am J Clin Nutr* **95**, 1323–1334.